Our series showed that only 42% of the IMT cases harbored gene fusion/rearrangement involving either ALK, NTRK3, and ROS1, but it has been shown that approximately 50%–70% of the IMTs harbor ALK fusion/rearrangement2,9. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.